CWS - ETF AI Analysis
Top Page
AdvisorShares Focused Equity ETF (CWS)
CWS, the AdvisorShares Focused Equity ETF, earns a solid overall rating largely because several core holdings like Comfort Systems USA (FIX), Amphenol (APH), and Mueller Industries (MLI) show strong financial performance, growth initiatives, and generally supportive technical trends. At the same time, positions such as McKesson (MCK) and Casey’s General Stores (CASY) introduce some drag through leverage, profitability, and bearish or mixed technical signals, and the fund’s focused approach means investors should be aware that concentrated exposure to a relatively small set of stocks can increase risk if any of these key names stumble.
CWS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 112.41M
- Region
- North America
- Expense Ratio
- 0.65%
- Beta
- 0.63
- Issuer
- AdvisorShares
- Inception Date
- Sep 20, 2016
- Dividend Yield
- 0.31%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
CWS Summary
AdvisorShares Focused Equity ETF (CWS) is an actively managed fund that aims to pick a select group of U.S. stocks across the total market, rather than tracking a fixed index. It focuses heavily on health care, technology, and industrial companies, with well-known names like McKesson and Thermo Fisher among its top holdings. Someone might invest in CWS for diversified exposure to different sectors and company sizes, with the potential for long-term growth through careful stock selection. A key risk is that, because it concentrates in certain sectors and individual stocks, its value can go up or down more than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, with a manager selecting and adjusting the fund’s stocks rather than just tracking a simple index.
What would affect this ETF?
This ETF is heavily invested in U.S. health care, technology, and industrial companies, so it could benefit if innovation, medical spending, and business investment stay strong and the U.S. economy grows steadily. On the downside, higher interest rates, slower economic growth, or new regulations affecting health care or technology could hurt company profits, and because the fund is actively focused on a relatively small set of stocks, poor stock selection could weigh more heavily on performance.
CWS Top 10 Holdings
CWS is leaning heavily on industrial and tech names, with Comfort Systems and IES Holdings acting as key engines of long‑term gains even though their recent stretch has been a bit mixed. Science Applications and Amphenol are steadier contributors, helping smooth out bumps with more consistent momentum. On the health care side, Thermo Fisher is rising and adds a high‑quality tilt, while McKesson’s more uneven trading keeps it from fully pulling its weight. With all holdings U.S.-based, this is a domestically focused, sector-diversified but industrial-tilted story.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 SAIC | Science Applications | 6.01% | $6.84M | $6.36B | 65.97% | 71Outperform |
 FIX | Comfort Systems | 5.80% | $6.61M | $43.13B | 27.96% | 80Outperform |
 CASY | Casey's General | 4.93% | $5.62M | $25.14B | 31.17% | 68Neutral |
 MCK | McKesson | 4.89% | $5.56M | $115.96B | 20.48% | 62Neutral |
 TMO | Thermo Fisher | 5.01% | $5.70M | $257.71B | 25.31% | 72Outperform |
 FDS | Factset Research | 4.49% | $5.12M | $11.62B | 22.50% | 78Outperform |
 HSIC | Henry Schein | 4.62% | $5.26M | $9.46B | 34.94% | 74Outperform |
 APH | Amphenol | 4.91% | $5.59M | $195.55B | 14.01% | 78Outperform |
 IESC | IES Holdings | 4.58% | $5.22M | $8.30B | 5.85% | 76Outperform |
 AWK | American Water | 4.39% | $5.00M | $28.74B | 13.95% | 73Outperform |
CWS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CWS, the sentiment is Negative. The current price of 67.04 is below the 20-day moving average (MA) of 67.73, below the 50-day MA of 68.83, and below the 200-day MA of 68.46, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 27.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CWS.
CWS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| CWS | $67.04 | $76.00(13.36% Upside) | $112.41M | 0.65% | 74Outperform |
 SEUS | $25.65 | $30.94(20.62% Upside) | $946.37M | 0.30% | 73Outperform |
 BGDV | $31.27 | $37.25(19.11% Upside) | $877.55M | 0.45% | 74Outperform |
 AAUB | $49.94 | $60.90(21.95% Upside) | $845.51M | 0.10% | 66Neutral |
 AVTM | $53.85 | $64.69(20.12% Upside) | $779.89M | 0.22% | 60Neutral |
 SMRI | $47.20 | $56.76(20.27% Upside) | $705.39M | 0.71% | 73Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CWS | AdvisorShares Focused Equity ETF | 67.04 | -0.13 | -0.20% | |
| SEUS | SEI QiM U.S. Equity Factor Allocation Active ETF | 25.65 | 0.39 | 1.53% | |
| BGDV | Bahl & Gaynor Dividend ETF | 31.27 | 5.03 | 19.16% | |
| AAUB | Alpha Architect US Equity 4 ETF | 49.94 | 0.45 | 0.91% | |
| AVTM | Avantis Total Equity Markets ETF | 53.85 | 4.21 | 8.47% | |
| SMRI | Bushido Capital US Equity ETF | 47.20 | 12.86 | 37.44% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.